drugset / Trial / NCT01046539
Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults
RandomizedCrossoverQuadruple-blindTreatment
Summary
This is a single site, double-blind, randomized, placebo-controlled, crossover study to assess the pharmacodynamics (PD) of RDC-0313 coadministered with buprenorphine in 12 healthy, opioid-experienced, non-treatment-seeking subjects.
Timeline
- Start
- 2010-01
- Primary completion
- 2010-03
- Completion
- 2010-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Samidorphan | Small molecule | 1 mg | — |
| Comparator | Samidorphan | Small molecule | 4 mg | — |
| Comparator | Buprenorphine | Other / unclassified | 8 mg | — |